Healthcare · Biotechnology
Price
$0.63
Market Cap
$995,979
Employees
52
Beta
1.03
Avg Volume
220,758
CEO
Michael Oster
Business Description
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Business History
Price Overview
Last updated: May 14, 2026 3:08am (just now)$0.63
-0.02 (-2.79%)
Day Range
$0.61 – $0.65
52-Week Range
$0.59 – $14.71
50-Day MA
$3.17
200-Day MA
$6.02
Volume
188,978.00
Analyst Price Targets
Low
$38.00
Consensus
$38.00
High
$38.00
(1 analysts)
Share Structure
Outstanding
1,593,567.00
Float
818,855.00
Free Float
51.4%
Normal free float
— 51.4% of shares trade freely, ~48.6% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (0.8M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.03
Stock Price: $0.63
EPS (Diluted): -22.19
EPS (Diluted): -22.19
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-100.26
Stock Price: $0.63
Total Equity: -$1.30M
Shares: 1,631,037,000
Total Equity: -$1.30M
Shares: 1,631,037,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.08
Market Cap: $995,979
Total Debt: $1.44M
Cash: $4.96M
EBITDA: -$32.29M
Total Debt: $1.44M
Cash: $4.96M
EBITDA: -$32.29M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$127.0M
Market Cap: $995,979
Total Debt: $1.44M
Cash: $4.96M
Total Debt: $1.44M
Cash: $4.96M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$2.92M
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$32.91M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$36.20M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-274.0%
Net Income: -$36.20M
Total Equity: -$1.30M
Total Equity: -$1.30M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-47.4%
Operating Income: -$32.91M
Tax Rate: 0.0%
Equity: -$1.30M
Total Debt: $1.44M
Cash: $4.96M
Tax Rate: 0.0%
Equity: -$1.30M
Total Debt: $1.44M
Cash: $4.96M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.87
Current Assets: $5.58M
Current Liabilities: $6.38M
Current Liabilities: $6.38M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-1.10
Short-Term Debt: $1.44M
Long-Term Debt: $0.00
Total Debt: $1.44M
Total Equity: -$1.30M
Long-Term Debt: $0.00
Total Debt: $1.44M
Total Equity: -$1.30M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 1,631,037,000
Shares: 1,631,037,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.00
Total Equity: -$1.30M
Shares: 1,631,037,000
Shares: 1,631,037,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.02
Operating CF: -$26.39M
CapEx: -$2,000
Shares: 1,631,037,000
CapEx: -$2,000
Shares: 1,631,037,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.63
Stock Price: $0.63
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$36.20M
Net Income: -$36.20M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PHGE against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: May 9, 2026 8:06pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $871,000 | $1.8M | $2.9M |
| Gross Profit | $0 | $0 | $-871,000 | -$1.8M | -$2.9M |
| Operating Expenses | $35.5M | $27.2M | $26.8M | $37.2M | $30.9M |
| Operating Income | -$35.5M | -$27.2M | -$27.7M | -$39.0M | -$32.9M |
| Net Income | -$36.2M | -$28.3M | -$26.2M | -$17.7M | -$36.2M |
| EBITDA | -$32.9M | -$23.7M | -$22.8M | -$13.1M | -$32.3M |
| EPS | $-264.67 | $-180.31 | $-96.90 | $-27.93 | $-22.19 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: May 9, 2026 8:06pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $62.1M | $31.3M | $14.9M | $17.8M | $5.0M |
| Total Current Assets | $66.6M | $36.9M | $17.6M | $20.5M | $5.6M |
| Total Assets | $78.0M | $45.5M | $25.0M | $43.2M | $70.2M |
| Current Liabilities | $11.0M | $7.9M | $11.2M | $8.3M | $6.4M |
| Long-Term Debt | $14.4M | $10.6M | $5.4M | $0 | $0 |
| Total Liabilities | $30.5M | $24.5M | $21.9M | $19.1M | $71.5M |
| Total Equity | $47.5M | $21.0M | $3.1M | $24.1M | -$1.3M |
| Retained Earnings | -$108.5M | -$136.8M | -$163.0M | -$180.7M | -$216.9M |
Cash Flow (Annual)
Last updated: May 9, 2026 8:06pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$27.6M | -$29.1M | -$21.3M | -$37.0M | -$26.4M |
| Capital Expenditure | -$3.7M | $-112,000 | $-50,000 | $-30,000 | $-2,000 |
| Free Cash Flow | -$31.3M | -$29.2M | -$21.3M | -$37.0M | -$26.4M |
| Acquisitions (net) | $4,000 | $0 | $0 | $663,000 | $110,000 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $25.9M | -$30.8M | -$16.4M | $2.1M | -$13.0M |
Analyst Estimates (Annual)
Last updated: May 14, 2026 3:08am (just now)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$23.5M $23.5M – $23.5M
|
$57.5M $57.5M – $57.5M
|
$13.8M $13.8M – $13.8M
|
$20.2M $20.2M – $20.2M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$9.5B -$9.5B – -$9.5B
|
-$9.8B -$9.8B – -$9.8B
|
-$7.5B -$12.2B – -$2.7B
|
-$51.4B -$51.4B – -$51.4B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: May 9, 2026 8:06pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | -107.0% | -62.1% |
| Operating Income Growth | +23.2% | -1.7% | -41.0% | +15.7% |
| Net Income Growth | +21.8% | +7.6% | +32.3% | -104.2% |
| EBITDA Growth | +28.1% | +3.6% | +42.5% | -146.0% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-16 | Yeganeh Reuven | S-Sale | 1,300,000.00 | $1.00 | $1.3M |
| 2026-03-16 | Yeganeh Reuven | S-Sale | 2,000,000.00 | $1.00 | $2.0M |
| 2026-03-17 | Yeganeh Reuven | C-Conversion | 530,000.00 | $2.00 | $1.1M |
| 2026-03-16 | Yeganeh Reuven | C-Conversion | 450,000.00 | $2.00 | $900,000 |
| 2026-03-16 | Yeganeh Reuven | C-Conversion | 900.00 | $2.00 | $1,800 |
| 2026-03-17 | Yeganeh Reuven | C-Conversion | 1,060.00 | $2.00 | $2,120 |
| 2026-03-17 | Yeganeh Reuven | S-Sale | 530,000.00 | $5.00 | $2.7M |
| 2026-03-16 | Yeganeh Reuven | S-Sale | 1,700,000.00 | $1.00 | $1.7M |
| 2026-03-13 | Yeganeh Reuven | C-Conversion | 370,000.00 | $2.00 | $740,000 |
| 2026-03-11 | Yeganeh Reuven | C-Conversion | 300,000.00 | $2.00 | $600,000 |
| 2026-03-12 | Yeganeh Reuven | C-Conversion | 600.00 | $2.00 | $1,200 |
| 2026-03-13 | Yeganeh Reuven | C-Conversion | 740.00 | $2.00 | $1,480 |
| 2026-03-13 | Yeganeh Reuven | S-Sale | 370,000.00 | $5.00 | $1.9M |
| 2026-02-13 | Bidas Liat Cohavi | 0.00 | $0.00 | $0 | |
| 2026-01-02 | Yeganeh Reuven | 3,300,000.00 | $2.00 | $6.6M | |
| 2026-01-02 | Yeganeh Reuven | 1,650,000.00 | $2.00 | $3.3M | |
| 2025-04-21 | Flynn James E | A-Award | 1,611,864.00 | $0.93 | $1.5M |
| 2025-04-14 | Merril Gregory Louis | A-Award | 17,600.00 | $0.54 | $9,469 |
| 2025-04-14 | Bassan Merav | A-Award | 95,000.00 | $0.54 | $51,110 |
| 2025-04-14 | Solomon Jonathan Eitan | A-Award | 380,500.00 | $0.54 | $204,709 |
No community reviews yet for PHGE.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.207 · 22a3a690 · 2026-05-13 17:39:54